AAA51971.1
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Related Accession #
NCBI Official Full Name
carcinoembryonic antigen
NCBI Official Synonym Full Names
carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)
NCBI Protein Information
carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)
UniProt Protein Name
Carcinoembryonic antigen
UniProt Entry Name
Q13985_HUMAN
NCBI Summary for CEACAM6
Carcinoembryonic antigen (CEA; MIM 114890) is one of the most widely used tumor markers in serum immunoassay determinations of carcinoma. An apparent lack of absolute cancer specificity for CEA probably results in part from the presence in normal and neoplastic tissues of antigens that share antigenic determinants with the 180-kD form of CEA (Barnett et al., 1988 [PubMed 3220478]). For background information on the CEA family of genes, see CEACAM1 (MIM 109770).[supplied by OMIM]
UniProt Comments for CEACAM6
CEACAM6: Belongs to the immunoglobulin superfamily. CEA family
Protein type: Membrane protein, integral; Membrane protein, GPI anchor
Chromosomal Location of Human Ortholog: 19q13.2
Cellular Component: integral to plasma membrane; plasma membrane
Molecular Function: protein binding
Biological Process: cell-cell signaling; blood coagulation; signal transduction; leukocyte migration
Research Articles on CEACAM6
1. CEACAM6-associated signaling pathways could be potential targets for the development of biomarkers to predict the response of patients to adenovirus-based therapies, as well as for the development of more potent adenovirus-based therapeutics2. Because CEACAM6 acts as an antiapoptotic factor and stabilizes surfactant function, in addition to a putative role in innate defense against bacteria, we propose that it is a multifunctional alveolar protein3. Data show that desensitization of neutrophils to any two CEACAMs, 1, 3, 6, or 8, results in selective desensitization to those two CEACAMs, while the cells remain responsive to the other two neutrophil CEACAMs.4. CEACAM6 is overexpressed in borderline and invasive mucinous ovarian neoplasms.5. findings suggest that CEA (CEACAM5) and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling.6. All the leukemic samples showed overexpression of CEACAM6 and 8 when compared with normal granulocytes.7. data support an important role for CEACAM6 in endocrine resistance in breast cancer, which can serve as a powerful predictor of future recurrence8. Observational study of gene-disease association. (HuGE Navigator)9. The expression of CEACAM6 in ADH lesions is strongly associated with the development of IBC, therefore, it can be applied as a diagnostic marker either singly or in combination with other marker(s) to predict IBC development in women with ADH lesions.10. CEACAM6 is a biological tumor marker for epithelial ovarian cancers.11. the results show that recognition of CEA and CEACAM6, but not CEACAM1, is accompanied by tight attachment to bacteria of cell surface microvilli-like extensions12. For all tumors, the amount of CEACAM6 expressed was greater than that of CEACAM5, and reflected tumor histotype.13. CEACAM6 subdomains involved in intercellular adhesion activity and subdomains involved in inhibition of cell differentation are identified and their respective activities are independently blocked.14. overexpression among human malignancies, immunological targeting of this tumor antigen may have therapeutic applicability15. Levels of CEACAM6 expression can modulate pancreatic adenocarcinoma cellular invasiveness in a c-Src-dependent manner16. Data show that variants of Neisseria gonorrhoeae that bind to human carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) 1 and 6 failed to induce detachment and, instead, promoted enhanced host cell adhesion to the ECM.17. CEACAM6 gene silencing reversed the acquired anoikis resistance of tumor cell lines and inhibited in vivo metastatic ability18. CEACAM6 is an important determinant of pancreatic adenocarcinoma malignant cellular behavior19. CD66c is regulated in a manner distinct from other myeloid antigens in childhood lymphoblastic leukemia20. Overexpression of CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated withanti-CEACAM6 antibody
Diseases associated with anti-CEACAM6 antibody
Organs/Tissues associated with anti-CEACAM6 antibody
| 
ELISA Kit
CLIA Kit
PCR Kit
Monoclonal Antibody
Polyclonal Antibody
Secondary Antibody
Antigen
Biochemical
cDNA Clone
siRNA
Peptide
Rec./Purified Protein
Custom ELISA Kit
Custom Protein
Custom Antibody
Antibody Matched Pairs
Antibody Peptide Pairs
Phospho Antibodies
Products by Disease
Products by Pathway
Products by Tissue